Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05641259 | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML | recruiting | Phase 1 | 198 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05875805 | A Telehealth Advance Care Planning Intervention(SICP RCT) | recruiting | N/A | 207 | University of RochesterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05884333 | Cord Blood Transplant in Adults With Blood Cancers | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06956755 | Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia | recruiting | — | 6,990 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06969430 | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 154 | Debiopharm International SAINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07328503 | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07387926 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | recruiting | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07616921 | A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant | recruiting | N/A | 30 | University of WashingtonOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07674823 | Study Of KITE-753 in R/R B-Cell ALL | not yet recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03104491 | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 44 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03953898 | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04940468 | High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology | completed | N/A | 8 | University of Colorado, DenverOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05969002 | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias | completed | — | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | recruiting | Phase 2 / Phase 3 | 216 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | withdrawn | Phase 1 | 0 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML(RAVEN) | not yet recruiting | Phase 2 | 88 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy(EVICTION 3) | not yet recruiting | Phase 2 / Phase 3 | 540 | IpsenINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07813208 | Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival(RWD-Ph+ ALL) | recruiting | — | 500 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | active not recruiting | N/A | 80 | University of West AtticaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814339 | Hydrochloroquinine & Decitabine With Venetoclax in AML | not yet recruiting | Phase 1 | 18 | Rutgers, The State University of New JerseyOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04049539 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | recruiting | Phase 1 / Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | active not recruiting | Phase 1 | 170 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | recruiting | Phase 3 | 650 | University of UlmOTHER | 8 | Sep 9, 2026 | clinicaltrials |
| NCT05320809 | Study of 3D189 in Patients With Hematologic Malignancies | completed | Phase 1 | 16 | 3D MedicinesINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06073730 | Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients | completed | Phase 3 | 154 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06303687 | VR-PAT and fNIRS to Identify CNS Biomarkers of Pain | not yet recruiting | N/A | 4 | Nationwide Children's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | active not recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06439199 | Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy(CYTOK-AZA) | recruiting | — | 60 | Nantes University HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06907797 | Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing | recruiting | N/A | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06954987 | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 244 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07062250 | Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia(HOME-BLOOD) | completed | N/A | 22 | Rigshospitalet, DenmarkOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | not yet recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07384715 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) | recruiting | Phase 1 | 78 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | not yet recruiting | Phase 1 / Phase 2 | 40 | Peking University People's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07809984 | Prevention of Oral Mucositis in Adults in With Hematologic Malignancy | not yet recruiting | N/A | 206 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810829 | Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML | not yet recruiting | — | 208 | Assiut UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT01044069 | Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | active not recruiting | Phase 1 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | completed | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment(INVISE) | active not recruiting | Phase 1 | 10 | Kite, A Gilead CompanyINDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials